Cognitive Enhancement Therapy for Alzheimer’s Disease

  title={Cognitive Enhancement Therapy for Alzheimer’s Disease},
  author={Lucilla Parnetti and Umberto Senin and Patrizia Mecocci},
SummaryAlthough at present there is no definitive treatment or cure for Alzheimer’s disease, different pharmacological strategies are being actively investigated. At present, cholinergic therapy and nootropics and some neuronotrophic agents represent the available approaches to symptomatic treatment of Alzheimer’s disease. The use of cholinesterase inhibitors (ChEI) constitutes the best cholinergic approach to increase acetylcholine levels. Available data suggest that about 15 to 40% of… Expand
Cognitive decline and dementia in the elderly hypertensive
JRAAS 2002;3 (suppl 1):S32–S38 Summary The prevention of cognitive disorders and dementia represents a major challenge in the coming years. The identification and management of the risk factors forExpand
General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia
The results indicate that cognitive flexibility is specifically impaired in deficit versus non-deficit patients and may therefore represent a core feature of this subtype of schizophrenia. Expand
Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease.
Compound 6 was the most potent multifunctional agent showing better inhibitory activity than ladostigil in vitro on all enzymes tested and the potent neuroprotective ability of compound 6 make it a promising compound for further development. Expand
Cognitive Enhancement Therapy for Adults with Autism Spectrum Disorder: Results of an 18-month Feasibility Study
It is suggested that CET is a feasible, acceptable, and potentially effective intervention for remediating the social and non-social cognitive impairments in verbal adults with autism. Expand
Neuroprotective and Antiamnesic Effects of Mitragyna inermis Willd (Rubiaceae) on Scopolamine-Induced Memory Impairment in Mice
The results suggest that M. inermis leaf extract possess potential antiamnesic effects, and reversed the effects of scopolamine in mice. Expand
Action-Based Cognitive Remediation for Individuals With Serious Mental Illnesses: Effects of Real-World Simulations and Goal Setting on Functional and Vocational Outcomes
Cognitive rehabilitative programs for serious mental illness that rely on computer-based training for neuroplasticity should ensure opportunities for active skill development and therapist-supported techniques to overcome challenges with generalizing cognitive effects to everyday outcomes. Expand
Non-fatal endpoints alone and combined with fatal endpoints Nature of endpoint Non-fatal endpoints Stroke Retinal exudates Cardiac endpoints Heart failure Myocardial infarction Renal failure Fatal and non-fatal endpoints Stroke
Subjects. Patients aged :<:: 60 years with sitting systolic blood pressure (BP) 160 219 mmHg and sitting diastolic BP< 95 mmHg during run-in phase. Methods and Results. Four thousand, six hundred andExpand
Synthesis and pharmacological evaluation of some new naphthol derived aryloxy derivatives as cognition enhancers
The present research was designed to describe the synthesis of a series of some 1-naphthol derivatives with their antiamnesic activity using mice as the animal model and piracetam as the referenceExpand
Towards the rational design of novel drugs based on solubility, partitioning/distribution, biomimetic permeability and biological activity exemplified by 1,2,4-thiadiazole derivatives.
The influence of the compound structure on the physicochemical properties determining the bioavailability of drug-like substances was revealed and Solubility-permeability interplay has been assessed to evaluate potentialBioavailability of the compounds studied. Expand
Antiamnesic Activity of Extracts and Fraction of Desmodium Gangeticum
Desmodium gangeticum D.C. (Salpani; family - Papilionaceae) has been traditionally used in the treatment of various ailments especially in dementia. Thus, it was planned to screen antiamnesicExpand


Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.
The results presented with SDZ ENA 713 indicate that the disadvantages of AChE inhibitors might be overcome by improving CNS selectivity and thereby decreasing the peripheral cholinergic effects and toxicity. Expand
Treatment of Alzheimer's disease: future directions
Protective approaches, which depend on the development of more effective methods for predicting and diagnosing AD, include the administration of nerve growth factor and other neurotrophins and the use of pharmacologic or genetic interventions to limit amyloid deposition and the formation of neurofibrillary tangles. Expand
Alzheimer's disease and related disorders.
The cholinesterase inhibitors provide the first clearly effective treatments for the cognitive deficits of AD and appear to have a beneficial effect on activities of daily living function andExpand
Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects
Senile dementia of the Alzheimer type (SDAT) is a degenerative disease of the brain that affects up to 20% or more of individuals who live beyond 80 years of age. A deficiency of cholinergic functionExpand
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients. Expand
Alzheimer disease : therapeutic strategies
This volume provides reviews of advances in basic and clinical sciences that are relevant to understanding the aetiology, pathogenesis and diagnosis of Alzheimer's disease, with particular emphasisExpand
Idebenone in senile dementia of Alzheimer type: a multicentre study.
Tolerability to idebenone treatment was good and was associated with a statistically significant improvement of memory, attention and behaviour, and it is worthwhile noting that these cognitive and behavioral findings were observed after the first month of treatment with enhancement evident in the following period. Expand
Treatment of Alzheimer's disease with cholinergic drugs.
  • V. Kumar, M. Calache
  • Medicine
  • International journal of clinical pharmacology, therapy, and toxicology
  • 1991
It is concluded that cholinergic drugs alone may not be the answer to treat Alzheimer disease patients and there seems to be a need to develop drug(s) which could affect several neurotransmitter or neuromodulator systems. Expand
Inflammatory mechanisms in Alzheimer's disease: implications for therapy.
There is ample evidence supporting the hypothesis that inflammatory and immune mechanisms are involved in tissue destruction in Alzheimer's disease and clinical trials of anti-inflammatory/immunosuppressive drugs are necessary to determine whether alteration of these inflammatory mechanisms can slow the progression of Alzheimer's Disease. Expand
Alzheimer's disease : basic mechanisms, diagnosis and therapeutic strategies
Partial table of contents: CLINICAL COURSE. Multidisciplinary Validation of Two Dementia Categories (N. Verma, et al.). NEUROPATHOLOGY: STRUCTURAL AND BIOCHEMICAL. Entorhinal Lesions in Dementia (H.Expand